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Background: The last decade has witnessed considerable improvement in dialysis technology and changes in
clinical management of patients in peritoneal dialysis (PD) with a significant impact on long term clinical outcomes.
However, the identification of factors involved in this process is still not complete.
Methods: Therefore, to assess this objective, we retrospectively analyzed clinical records of 260 adult patients who
started PD treatment from 1983 to 2012 in our renal unit. For the analysis, we divided them into three groups
according to the time of starting dialysis: GROUP A (n: 62, 1983–1992), GROUP B (n: 66, 1993–2002) and GROUP C
(n: 132, 2003 to 2012).
Results: Statistical analysis revealed that patients included in the GROUP C showed a reduction in mean patients’
age (p = 0.03), smoking habit (p = 0.001), mean systolic blood pressure (p < 0.0001) and an increment in
hemoglobin levels (p < 0.0001) and residual diuresis (p = 0.016) compared to the other two study groups.
Additionally, patients included in GROUP C, mainly treated with automated peritoneal dialysis, showed a reduced
risk of all-causes mortality and a decreased risk to develop acute myocardial infarction and cerebrovascular disease.
Patients’ age, diabetes mellitus and smoking habit were all positively associated with a significant increased risk of
mortality in our PD patients, while serum albumin levels and residual diuresis were negatively correlated.
Conclusions: Therefore, the present study, revealed that in the last decade there has been a growth of our PD
program with a concomitant modification of our patients’ characteristics. These changes, together with the evident
technical advances, have caused a significant improvement of patients’ survival and a decrement of the rate of
hospitalization. Moreover, it reveals that our pre-dialysis care, modifying the above-mentioned factors, has been a
major cause of these clinical improvements.
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Chronic kidney disease (CKD) is a progressive and irre-
versible deterioration of kidney function classified by the
last international guidelines into five stages according to
glomerular filtration rate [1]. In the last phase (end stage
renal disease, ESRD) the kidney impairment is advanced
and cellular/metabolic functions are significantly altered
and enable to guarantee normal body homeostasis. Conse-
quently, at this stage, renal replacement therapies (RRTs,
peritoneal- or hemo-dialysis) or renal transplantation are
needed to ensure patient’s survival.* Correspondence: Gianluigi.zaza@univr.it
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unless otherwise stated.Although hemodialysis (HD) still represents the lead-
ing RRT, peritoneal dialysis (PD) procedure is utilized in
more than 150,000 patients world-wide with a prevalence
in Europe of 16% and in USA of 8% [2]. Recent data from
the Italian Study Group of Peritoneal Dialysis have re-
ported an incidence of this dialysis modality of approxi-
mately 20% with a prevalence of 15% [3,4].
PD seems to be a preferable choice for younger patients
with high life expectancy and an elevated probability to
undergo renal transplantation. In fact, this dialysis modal-
ity offers more flexibility allowing patients to continue
working, a lesser cardiovascular impact and the mainten-
ance of residual diuresis [5-7].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(characterized by high concentration of glucose, glu-
cose degradation products, low pH and high osmolal-
ity) used to remove waste products generated from
normal metabolic processes, uremic toxins and to
normalize body fluid and electrolytes [8] may still de-
termine the systemic activation of a complex intracel-
lular machinery leading to inflammation and oxidative
stress [9-11]. These conditions may induce systemic
non-infectious clinical complications including cardio-
vascular diseases.
Furthermore, recent studies have identified several
demographic factors (e.g., age > 75 years at the start of
dialysis, BMI <18), clinical features (e.g., ischemic heart
disease, anemia, heart failure and hemodynamic overload,
cerebral vascular disease, peripheral vascular disease, dia-
betes) and metabolic causes (e.g., diabetes mellitus) associ-
ated with higher risk of mortality in PD patients compared
with general population [12,13].
However, at the moment, only few reports have pointed
out on the identification of risk factors for long-term clin-
ical complications in PD patients living in Italy or other
European countries [14-16]. It is unquestionable that
geographically-related characteristics (e.g., diet, health care
system), enhancing risk factors, may influence long term
clinical outcomes.
Therefore, although monocentric, our study, performed
on a large Italian cohort of PD patients (including 260 pa-
tients followed by our Renal/Dialysis Unit from 1983 to
2012), has been undertaken to identify changes across the
last 30 years, to select clinical elements possibly predicting
patients’ survival and to recognize targets of intervention
useful to minimize the onset and development of severe
dialysis-associated clinical complications.
Methods
Patients
In this study, we retrospectively analyzed clinical records of
260 adult patients (older than 18 years) who started PD at
the Renal Unit of the Hospital-University of Verona from
1983 to 2012.
Patients with fewer than 6 months’ follow-up, who
had been on HD or receiving a kidney graft before start-
ing PD and had experienced at least one major cardio-
vascular event (myocardial infarction or cerebrovascular
events, or who have undergone amputation) before dia-
lysis were excluded.
Patients were, then, divided into 3 groups according to
the time of starting PD:
 GROUP A (n: 62): patients starting PD from 1983
to 1992;
 GROUP B (n: 66): patients starting PD from 1993
to 2002; GROUP C (n: 132): patients starting PD from 2003
to 2012.
For all patients, we collected main demographic and
clinical characteristics (Table 1). Estimated glomerular
filtration rate (eGFR) has been calculated according to
Cockcroft-Gault equation.
The study was carried out according to Declaration of
Helsinki principles and approved by the Institutional Ethic
Review Board of the University of Verona, Italy. All pa-
tients signed an informed consent.
Statistical analysis
All data were expressed as frequencies, percentages and
mean values or median according to the variables’ distri-
bution. Parametric (t-test, ANOVA) and non-parametric
(Mann–Whitney, Kruskal Wallis test) test and chi-square
test/fisher test were used to assess differences in clinical
and demographic features. Incidence rates of adverse
events were calculated using the Poisson distribution and
survival analysis was performed using Kaplan-Meier. Cox
regression model was used to estimate the risk of acute
myocardial infarction, cerebrovascular disease and vas-
culopathy. Tests have been corrected for baseline con-
founding factors as required. All tests were considered
significant when p < 0.05. All statistical analysis were
performed using SPSS, version 11.5.
Results
Demographic and clinical characteristics overtime
As showed in Table 1, we found significant differences
in several demographic and clinical variables among the
three study periods.
Statistical analysis revealed a significant and progressive
reduction of the mean patients’ age (p = 0.03), smoking
habit (p = 0.001), mean systolic blood pressure (p < 0.0001)
across the study periods. On the contrary, hemoglobin
levels (p < 0.0001) and residual diuresis (p = 0.016) were
increasing overtime.
Choice of PD methods
From 1983 to 2012, we found a clear trend toward in-
creased number of PD patients undergoing automated
peritoneal dialysis (APD) (p < 0.0001). This could reflect
a change of the demographic characteristics of our PD
population (younger and still able to work) (Figure 1A).
Waiting list for renal transplantation
During time, we found a significant increased number of
PD patients on active renal transplant waiting list (p <
0.0001). This reflects a change of our center policy (mainly
in the last decade) to use PD preferentially in younger pa-
tients without major comorbidities (e.g., cardio-vascular
diseases, malignancies) (Figure 1B).
Table 1 Trends in demographic and clinical characteristics among the three study periods
GROUP A GROUP B GROUP C p value
1983-1992 (n = 62) 1993-2002 (n = 66) 2003-2012 (n =132)
Follow-up months mean (SD) 29.3 (25.1) 36.6 (27.4) 33.7 (26.9) 0.298
*Age years mean (SD) 63.5 (9.0) 59.7 (12.7) 59.0 (12.0) 0.038
Gender
Males n. (%) 36 (58.1) 46 (69.7) 94 (71.2) 0.174
Females n. (%) 26 (41.9) 20 (30.3) 38 (28.8)
Smoking habits
No smokers n. (%) 51 (82.2) 39 (59.1) 77 (58.3) 0.001
Ex smokers n. (%) 7 (11.3) 11 (16.7) 38 (28.8)
Smokers n. (%) 4 (6.5) 16 (24.2) 17 (12.9)
*Diabetes
No diabetes n. (%) 44 (71.0) 52 (78.8) 102 (77.3) 0.532
Diabetes n. (%) 18 (29.0) 14 (21.2) 30 (22.7)
*Residual diuresis ml/die mean (SD) 777.8 (560.0) 924.2 (460.4) 997.7 (469.2) 0.016
*Systolic blood pressure mmHg mean (SD) 159.6 (25.2) 154.0 (19.9) 140.5 (15.4) <0.0001
*Albumin g/dl mean (SD) 3.4 (0.49) 3.2 (0.5) 3.9 (2.8) 0.06
*Hb g/dl mean (SD) 8.7 (1.5) 9.6 (7.5) 11.7 (1.36) <0.0001
*eGFR mean (SD) 6.1 (1.9) 6.4 (2.4) 6.9 (2.6) 0.076
eGFR: estimated Glomerular Filtration Rate. (*) At the start of PD treatment.
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Multivariate analysis (Figure 2) showed that patients’ age
(hazard ratio (HR): 1.1, p = 0.001), diabetes mellitus (HR:
3.9, p <0.001) and smoking habit (HR: 1.3, p <0.001) were
all positively associated with an increased risk of all-causes
mortality in our PD patients’ population, while serum al-
bumin levels (HR: 0.6, p = 0.001) and residual diuresis
(HR: 0.9, p = 0.04) were negatively correlated.
Gender, systolic blood pressure, hemoglobin levels and
eGFR were not associated with patients’ survival.
Kaplan-Meier revealed a better survival rate in PD pa-
tients of GROUP C compared to those included in the
other two study-groups (Figure 3). Similar results were
obtained evaluating transplantation and change in dialysis
modality as competing outcomes and risks (Additional
file 1: Table A and B, Figure S1). In particular, the statis-
tical analysis confirmed a significantly higher risk of death
in GROUP A versus both GROUP B and C (p < 0.0001)
and an higher probability to undergo renal transplantation
in last study period (GROUP C) compared to the other
two periods (GROUP B and A) (p < 0.0001). On the con-
trary the risk to switch from PD to HD was similar among
the three groups.
Interestingly, analyzing the trajectories of some of the
above-mentioned clinical variables over-time (5 years),
hemoglobin levels resulted constantly higher in GROUP
C compared to B and A (Additional file 1: Table C).This could mainly be due to a complete correction of
anemia (with a more rational use of ESAs) in the last
10 years.Risk of cardiovascular diseases
As shown in Figure 4, there was a gradual reduction in
the risk of developing acute myocardial infarction and
cerebrovascular complications overtime.
We did not find any statistically significant difference
in the risk of vascular disease.Days of hospitalization and complications
Interestingly, patients included in GROUP C showed a
lower period of overall hospitalization for all causes and
peritonitis compared to Group B and A (Figure 5).
The major causative agents of peritonitis were Staphylo-
coccus Aureus and Epidermidis followed by Pseudomonas
Aeruginosa (Table 2). This condition was similar in the 3
study groups.
Technique and catheter survival after one episode of
peritonitis were considerably higher in the last study
period (GROUP C: 2003–2012) compared to the other
two periods.
Overall technique survival was similar in the 3 groups.
No catheter has been surgically removed and re-inserted
after a peritonitis episode (according to Hospital policy).
Figure 1 Patients’ distribution according to peritoneal dialysis (PD)
modalities and percentage of patients on the waiting list for renal
transplantation in the three study periods. The histograms represent
(A) the percentage of patients on CAPD: Continuous Ambulatory
Peritoneal Dialysis or APD: automated peritoneal dialysis and (B) the
percentage of PD patients on the waiting list for renal transplantation
in the three study groups. Group A: 1983–1992; Group B: 1993–2002;
Group C: 2003–2012. P values calculated by fisher exact test.
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Peritoneal dialysis (PD), although considered a valu-
able alternative renal replacement therapeutic option to
hemodialysis (HD) in a great number of CKD patients
(mainly young), is still associated with the development of
severe long-term clinical complications (e.g., cardiovascular
diseases) leading to significant reduction of patients’ sur-
vival [17].
Therefore, in the last decade, researchers and clinicians
worldwide had work together to avoid or minimize these
complications by introducing more “biocompatible” fluids
(with more physiologic pH and reduced glucose degrad-
ation products) and by ameliorating the selection of eli-
gible patients for this dialysis procedure [18,19].
Additionally, several strategies have been undertaken
to minimize, particularly during the pre-dialysis follow-
up period, all corrigible factors known to be associatedwith worst clinical outcomes of PD patients [20]. How-
ever, the complete identification of these elements repre-
sents a major target in nephrology.
To this purpose, we retrospectively analyzed our med-
ical records regarding a large CKD patients cohort (n:260)
starting PD treatment from 1983 to 2012.
Interestingly, several factors were significantly associ-
ated with an increased risk of mortality in our PD pa-
tients. Multivariate analysis showed that patients’ age,
diabetes mellitus and smoking habit were all positively
associated with an increased risk of all-causes mortality
in our PD patients’ population.
The impact of age on survival is still debated. In fact,
as a continuous home-based therapy, PD offers several
potential advantages for older people, and it remains an
important modality of renal replacement therapy, but
patients with advanced age have an high risk to develop
clinical complications and undergo peritonitis [21-24]
However, in a recent paper, Nessim et al. did not find
any relationship between peritonitis and older age in
the subgroup of patients who initiated dialysis in more
recent years (2001 – 2005) [25] probably because of the
recent advances in PD connection methods and exit-
site care [26].
Also diabetes has been previously associated with
worst outcomes in PD patients. Duong et al. have re-
cently reported that a poor glycemic control (A1c ≥8%
or serum glucose ≥300 mg/dl) appears to be associated
with a decreased survival in PD patients. Authors sug-
gested also that a better glycemic control could slow
down the progression of microvascular disease and loss
of residual renal function [27].
Therefore, to improve the management of diabetic
patients undergoing PD represents a great challenge in
nephrology.
To this purpose, icodextrin use has been encouraged
in this large patients’ population. The benefit of this
colloid osmotic agent, derived from maltodextrin, has
been recently evaluated by Paniagua et al. in a prospect-
ive, randomized controlled trial in 60 diabetic patients
undergoing PD [28]. These authors demonstrated that
icodextrin, as compared with conventional glucose solu-
tion, reduces blood glucose concentration, a finding that
was accompanied by a concomitant improvement in
HbA1c and a reduction in insulin dosage. In addition,
icodextrin-treated PD patients necessitated of a lower
food intake.
Our study, then, reported that PD patients were highly
vulnerable to the adverse consequences of smoking. This
is in line with a paper published by Braatvedt et al.
describing, in a large New Zealand database (more than
1000 patients), an higher age-adjusted mortality rate in
PD patients with a history of current or former smoking
compared to non-smokers [29].
Figure 2 Multivariate Cox proportional hazard model for mortality according to several demographic and clinical characteristics. In this model are
indicated Hazard ratio (HR) and 95% Coefficient interval (CI) for each factor analyzed. CVD: cardiovascular disease.
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uresis were negatively associated with the risk of mortal-
ity for all-causes in our PD patients’ population.
In the past, serum albumin has been shown to predict
all-cause mortality, and peritonitis risk in PD patients;Figure 3 Survival rate in the three study groups by Kaplan-Meier. Survival
B: 1993–2002 and Group C: 2003–2012). Survival rate was better in Group Chowever, the data are significantly more limited than for
HD patients and most of the time based on small re-
search studies [30-33].
The biological basis for the association of hypoalbumin-
emia with mortality remains uncertain. A main reasonrate of patients in the three study groups (Group A: 1983–1992, Group
compared to the other two groups.
Figure 4 Incidence rate ratio of acute myocardial infarction (A), cerebrovascular disease (B) and vasculopathy (C) according to the three study
groups. Group A: 1983–1992; Group B: 1993–2002; Group C: 2003–2012. Figure has been built on the basis of Cox analysis.
Figure 5 Days of hospitalization in the three study periods. The
histograms represent the mean ± SD of the days of hospitalization
for all causes (white bars) and peritonitis (gray bars) in each
study group. Group A: 1983–1992; Group B: 1993–2002; Group
C: 2003–2012.
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(5–10 g/protein per day) in the dialysate effluent [34]. On
the contrary, several researchers believe that since albu-
min is a negative acute phase reactant, this association in
dialysis patients is secondary to the confounding influence
of systemic inflammation [35]. A recent cross-sectional
study of PD patients suggests that many of the patients
with hypoalbuminemia are volume overloaded and hyper-
volemia may be an additional confounding influence [36].
Residual diuresis was the other clinical factor negatively
associated with mortality in our PD patients confirming
previous literature evidences reporting that a residual
renal function (RRF) favoring the clearance of middle
molecules, sodium removal and better control of vol-
ume status could have positive cardiovascular and sys-
temic effects [37,38].
Moreover, as additional results of our study, we found
a significant change of some of the above-mentioned
mortality risk factors overtime. Mean patients’ age and
smoking habit were reduced, while residual diuresis raised
during-time.
We suppose that all these positive modifications have
been possible thanks to the implementation in our Renal
Table 2 Frequency of occurrence of peritonitis and overall/post-peritonitis technique survival in the three study
periods
GROUP A (1983–1992) GROUP B (1993–2002) GROUP C (2003–2012)
Culture negative peritonitis (CNP) 35% 25% 17%
Culture positive peritonitis (CPP) 65% 75% 83%
Staphylococcus aureus (% of total CPP) 20% 17% 19%
Staphylococcus epidermidis (% of total CPP) 40% 40% 36%
Pseudomonas (% of total CPP) 20% 18% 16%
Othergram-negativeorganisms (includingKlebsiella, Serratia and
Enterobacter species) (% of total CPP)
15% 17% 18%
Other organisms (% of total CPP) 5% 8% 11%
Post-peritonitis technique survival (at 1 year after peritonitis) 58% 75% 85%
Overall technique survival (at 5 years) 63% 73% 79%
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egy by a dedicated multi-disciplinary team (involving
medical doctors, nurses, psychologists, nutritionists) that,
personalizing medical assistance, ensures an adequate
metabolic balance, a good correction of anemia (with the
more rational use of ESAs) and an implementation of all
possible strategies to maintain the residual diuresis (for
example by limiting the use of nephrotoxic drugs and by
an overfluid control). Additionally, the correct education
of our PD patients has increased their therapeutic compli-
ance/adherence, reduced/stopped smoking habit and im-
proved dietary intake.
In the last decade, then, this multi-disciplinary pre-
dialysis program, together with the reduction of our
patients’ age, has been responsible of the significant in-
crement of PD patients undergoing APD modality (p =
0.0001). The APD, giving the possibility to continue to
work and to maintain familial and social activities, can
be considered a good “bridge” between CKD and renal
transplantation (as showed in Figure 1A, at the moment,
patients added to the waiting list for transplantation are
more than 30%).
Other factors modified during the study periods were
hemoglobin levels (increased) and systolic blood pres-
sure (decreased). Both represent well known risk factors
for cardiovascular mortality in the general and PD popu-
lation [39,40].
This can partially justify the significant decreased risk
of death for acute myocardial infarction and cerebrovas-
cular complications in our PD patients overtime.
Conclusions
Therefore, the present study, although limited by the
exclusion of other important factors that could influence
clinical outcomes (including nutritional status, periton-
eal transport characteristics) and absence of a control
group (i.e., patients undergoing hemodialysis treatment)
clearly underlines that in the last decade there has beena significant increment in the number of patients under-
going PD and a profound change in their demographic
and clinical characteristics.
Patients are younger, no smokers, with a residual diur-
esis, normal hemoglobin level and lower blood pressure.
All these changes have definitely improved patients’ sur-
vival (all-causes and cardiovascular diseases) and caused
a fall of the hospitalization rate. Moreover, our pre-
dialysis care, modifying most of the above reported risk
factors, has been a major actor of the clinical improve-
ment observed in our PD patients’ population in the last
10 years.
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